Journal of global antimicrobial resistance · 2018
Potent in vitro antileishmanial activity of a nanoformulation of cisplatin with carbon nanotubes against Leishmania major.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Akhtari Javad, Faridnia Roghiyeh, Kalani Hamed, Bastani Reza, Fakhar Mahdi, Rezvan Hossein, Beydokhti Amin Kazemi
Аннотация
OBJECTIVES: The aim of this study was to evaluate the cytotoxicity and antileishmanial activity of cisplatin-bonded carbon nanotubes both against promastigotes and amastigotes of Leishmania major in vitro.
METHODS: Cisplatin-bonded single-walled carbon nanotubes (CP-SWCNT) and cisplatin-bonded multi-walled carbon nanotubes (CP-MWCNT) were considered as test compounds. In addition, SWCNT, MWCNT, free cisplatin and meglumine antimoniate (Glucantime®) were considered as controls. The effect of each compound was evaluated both on promastigote and amastigote stages of L. major and the results were compared.
RESULTS: There was a statistically significant difference between the half-maximal inhibitory concentration (IC50) of CP-SWCNT and each of the controls, including SWCNT, cisplatin and Glucantime® (P<0.05). In addition, IC50 values of CP-MWCNT and each of the controls, including MWCNT, cisplatin and Glucantime®, were significantly different both for promastigotes and amastigotes (P<0.05). However, the selectivity index (SI) of CP-SWCNT was <10 (5.23), indicating that this compound is not completely safe. Moreover, the SI values of CP-MWCNT (12.54) and Glucantime® (16.28) were >10, indicating the selective effect of these two compounds on the parasite. Moreover, the IC50 of CP-MWCNT (0.11±0.09μM) for amastigotes was 41-fold lower than that of Glucantime® (4.52±1.31μM), suggesting that a lower dose of CP-MWCNT in comparison with Glucantime® is required to kill 50% of amastigotes.
CONCLUSIONS: According to the potent in vitro antileishmanial activity of CP-MWCNT at low concentration against L. major, we suggest that they are evaluated in an animal model.
METHODS: Cisplatin-bonded single-walled carbon nanotubes (CP-SWCNT) and cisplatin-bonded multi-walled carbon nanotubes (CP-MWCNT) were considered as test compounds. In addition, SWCNT, MWCNT, free cisplatin and meglumine antimoniate (Glucantime®) were considered as controls. The effect of each compound was evaluated both on promastigote and amastigote stages of L. major and the results were compared.
RESULTS: There was a statistically significant difference between the half-maximal inhibitory concentration (IC50) of CP-SWCNT and each of the controls, including SWCNT, cisplatin and Glucantime® (P<0.05). In addition, IC50 values of CP-MWCNT and each of the controls, including MWCNT, cisplatin and Glucantime®, were significantly different both for promastigotes and amastigotes (P<0.05). However, the selectivity index (SI) of CP-SWCNT was <10 (5.23), indicating that this compound is not completely safe. Moreover, the SI values of CP-MWCNT (12.54) and Glucantime® (16.28) were >10, indicating the selective effect of these two compounds on the parasite. Moreover, the IC50 of CP-MWCNT (0.11±0.09μM) for amastigotes was 41-fold lower than that of Glucantime® (4.52±1.31μM), suggesting that a lower dose of CP-MWCNT in comparison with Glucantime® is required to kill 50% of amastigotes.
CONCLUSIONS: According to the potent in vitro antileishmanial activity of CP-MWCNT at low concentration against L. major, we suggest that they are evaluated in an animal model.